We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Canada Cracks Down on Generic Pay-for-Delay Agreements
Canada Cracks Down on Generic Pay-for-Delay Agreements
The Canadian government is ratcheting up scrutiny of patent litigation settlements between brand and generic drugmakers in attempt to prevent antitrust deals that delay generic competition.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor